DFURegen conducted global clinical studies and demonstrated that a single treatment of AMHAT stimulates wound healing by accelerating re-epithelialization of the chronic wound site. AMHAT is derived from patient’s own (autologous) adipose tissue composed of hundreds of proteins, growth factors and cytokines that are essential for wound-healing. In addition to autologous solution, disruptive 4D bioprinting technology delivers customized therapy for healing of refractory diabetic foot ulcers. This is a potent alternative approach for the diabetic patients suffering from non-healing chronic wounds, providing an opportunity for patients to live a better life.